20150402 smb inno boot gatt
TRANSCRIPT
Presentation Radboud Innovatie BootCamp 2015 Rob Lips
Nijmegen, 2 april 2015 GATT Technologies BV
GATT-Patch
Strategic or Financial investors?
GATT™ synthetic polyoxazoline (POX) platformfor surgical sealants and hemostats
GATT-Tape GATT- Patch
AgendaFrom POX polymer to medical device business opportunity
14 April 2015 GATT Technologies BV 2
About GATT Technologies BV
The GATT-Patch product opportunity
The GATT-Patch industry opportunity
Strategy and financing
Johan Bender MSc Prof Harry v Goor CEO, founder clinical partner serial entrepreneur
About GATT founded with a clinical ambition
14 April 2015 GATT Technologies BV 3
“The GATT technology platform will enable medical device tapes and patches
with specific properties optimized for the targeted clinical
application”
GATT Technologies BV :
founded in 2011 by Johan Bender
The unmet need :
anastomotic leakage: 3-15% with mortality 2-3%
The ambition : the GATT-Tape
About GATTGATT-Tape : technology and successful proofs of concept
14 April, 2015 4
Approved PEG (Polyethyleneglycol ) sealant products
DuraSeal: CoSeal:
Successful Proofs of Concept
GATT-POX advantages over PEG
strong adhesion on wet tissue
water tight < 1-2 minutes
GATT-Tape production
Hot Melt Extrusion
POX poly(2-oxazoline)s has additional benefits:
stronger adhesion better tuneable functionality non-brittle
PEG POX
+ End and side chains+ Versatile synthesis
GATT Technologies BV
GATT-Tapeneeded milestones and financing
14 April, 2015 GATT Technologies BV 5
GATT Technologies BV
Strategic Partner
GATT Tape
Technical Proof-of-Concept
X M€
GATT Tape
Pre-Clinical Studies
GATT Tape
Clinical StudiesMilestone CE
GATT Tape
Market intro first Sales
0.X M€ X M€*
X M€ X M€
2015 2016 2018
* intended innovation loans
0.XM€
Financial InvestorsSubsidies/Loans
Financial Investors ?
The large hemostatic and sealant market trend to (semi) synthetic medical devices
14 April 2015 6
productcosts
adhesion strength
Hemostats Sealants
*time to hemostasis
medical device
medicine
2005
Mechanicalhemostats
(1-10 min.)*
PEGsealants
(<2 min.)*
GATT Technologies BV
Fibrinpowders(<3 min.)*
Fibringels
(<3 min.)*Fibrin
spray sealants(<5-10 min.)*
Fibrinpatches
(<3 min.)*
POXGATT-Tape
(seal)
POXGATT-Tape
(seal)
The product opportunityclinical need for cost-effective, high-end hemostats
14 April 2015 7
productcosts
adhesion strength
Hemostats Sealants
*time to hemostasis
medical device
medicine
Fibrinpatches
(<3 min.)*
2005
Mechanicalhemostats
(1-10 min.)*
2014 PEGpatches
(<2 min.)*
GATT Technologies BV
POXGATT-Patch
(<1 min)*
GATT-Patch> equal/better than Baxter Hemopatch
2017
GATT-Patchcost effective solution in expanding market segment
14 April, 2015 8
The opportunity: Baxter HemoPatch slipstream
BAXTER, recently introduced the Hemopatch
(a sealing hemostat):
PEG-collagen based
hemostatic medical device
competitive pricing
The GATT-Patch will have equal or better
characteristics than the BAXTER Hemopatch
Especially on the faster time to hemostasis (< 1 min.) and at least equal cost effectiveness.
The GATT-Patch will be an attractive and profitable
completion of the product portfolio for most of the major vendors
expensive time to hemostatis 3 min.
The targeted GATT-Patch product
GATT Technologies BV
The industry opportunitymarket shift to cost-effective, semi-synthetic medical devices
14 April 2015 9
productcosts
adhesion strength
Hemostats Sealants
*time to hemostasis
medical device
medicine
Fibrinpatches
(<3 min.)*
PEGpatches
(<2 min.)*
POXGATT-Patch
(<1 min)*
1
Mechanicalhemostats
(1-10 min.)*
2
GATT Technologies BV
The industry opportunitytargeted companies and confirmed interest
14 April 2015 10
1. Market players with expensive fibrin hemostats:
a competitive high end “sealing” hemostat, is a must for their sales channels
the GATT POX technology will allow for a complete competitive, cost-effective hemostat portfolio
2. Market players with traditional mechanical hemostats:
enables shift of portfolio and expansion of business to attractive high-end
GATT-Patch industry target Matrix:
GATT Technologies BV
* <= level as PEG
<< lower than Fibrin
The product opportunity Profitable turnover
14 April, 2015 11
Value chain Turnover
The turnover potential for the GATT-Patch is estimated at 50-150M€ at a targeted 10-20% share in the high end market.
First sales will start at the end of 2017 with a targeted sales turnover of 10-20M€ after 5 years
GATT Technologies BV
GATT-Patch BVStrategy: separate legal entity with full business ownership
14 April, 2015 GATT Technologies BV 12
GATT Technologies BV
IP POX technology platform product development supply of activated POX
Strategic Partner
approved carrier + know-how production co-investment (distribution)
GATT Patch BV
business and product owner
exclusive rights on hemostat technology
large OEM partners distributors*
*independent and/or from strategic partner
product supply
GATT-Patch BVdeal construction for partnership GATT-Strategic Partner
14 April, 2015 GATT Technologies BV 13
GATT Technologies BV
Strategic Partner
GATT Patch BV
Technical Proof-of-Concept
GATT-Tech 100%
X M€
GATT Patch BV
Pre-Clinical Studies
GATT-Tech 90%Partner 10%
GATT Patch BV
Milestone CEClinical Studies
GATT-Tech 75%Partner 25%
GATT Patch BV
Market intro operational sales
endorsement studiesGATT-Tech 50%Partner 50%
0.X M€ X M€*
X M€ X M€
2015-Q2 2016-Q2 2017
* intended innovation loans
0.XM€
GATT-Patch
Strategic or Financial investors?
GATT-Tape
Financial Investor
GATT- Patch
Strategic Investor
GATT Technologies BV Rob Lips [email protected]